ACADIA Pharmaceuticals
Update in progressACAD (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
ACADIA Pharmaceuticals is a biopharmaceutical company focused on therapies for neurological and rare diseases in North America. It markets NUPLAZID (pimavanserin) for Parkinson’s disease psychosis and DAYBUE, a synthetic IGF-1 analog for Rett syndrome. It also develops multiple programs in various trial phases, and has partnerships with Neuren and Stoke Therapeutics. Headquartered in San Diego, California.
Company score
- Sentiment
- -0.20
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.01
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.15
- Governance
- -0.42
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.13
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!